E-LIB Suche - Ergebnisse für: Al-Sawaf, Othman

1

High-risk stays high-risk: Bruton tyrosine kinase inhibitor..:

Al-Sawaf, Othman
Haematologica. , 2024

Link: https://doi.org/10.3324/..

2

Chronic Lymphocytic Leukemia: Time-Limited Therapy in the F..:

Stumpf, Janina ; Al-Sawaf, Othman
Current Oncology Reports. 26 (2024) 2 - p. 136-146 , 2024

Link: https://doi.org/10.1007/..

3

CLL-465 Second Primary Malignancies (SPMs) in Patients With..:

Goergen, Ellinor ; Tresckow, Julia v. ; Giza, Adam...
Clinical Lymphoma Myeloma and Leukemia. 24 (2024) - p. S354-S355 , 2024

Link: https://doi.org/10.1016/..

4

Venetoclax-Obinutuzumab for previously untreated chronic ly..:

Al-Sawaf, Othman ; Robrecht, Sandra ; Zhang, Can...
Blood Journal. , 2024

Link: https://doi.org/10.1182/..

5

Second Primary Malignancies (SPMs) in Patients With Chronic..:

Goergen, Ellinor ; Tresckow, Julia v. ; Giza, Adam...
Clinical Lymphoma Myeloma and Leukemia. 24 (2024) - p. S182 , 2024

Link: https://doi.org/10.1016/..

6

P622: GENETIC MARKERS AND OUTCOME OF CLL PATIENTS IN COMBIN..:

Yosifov, Deyan ; von Tresckow, Julia ; Giza, Adam...
HemaSphere. 7 (2023) S3 - p. e14818fb , 2023

Link: https://doi.org/10.1097/..

7

EXABS-208-CLL MRD+ at 1 Year of VenG: Stop Therapy:

Al-Sawaf, Othman
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S96-S97 , 2023

Link: https://doi.org/10.1016/..

8

Transcriptomic profiles and 5-year results from the randomi..:

Al-Sawaf, Othman ; Zhang, Can ; Jin, Hyun Yong...
Nature Communications. 14 (2023) 1 - p. , 2023

Link: https://doi.org/10.1038/..

9

Body composition and lung cancer-associated cachexia in TRA..:

Al-Sawaf, Othman ; Weiss, Jakob ; Skrzypski, Marcin...
Nature Medicine. 29 (2023) 4 - p. 846-858 , 2023

Link: https://doi.org/10.1038/..

10

Importance of Minimal Residual Disease in the Era of Target..:

Al-Sawaf, Othman
Acta Haematologica. 147 (2023) 1 - p. 22-32 , 2023

Link: https://doi.org/10.1159/..

11

Pirtobrutinib versus venetoclax in covalent Bruton tyrosine..:

Al-Sawaf, Othman ; Jen, Min-Hua ; Hess, Lisa M...
Haematologica. , 2023

Link: https://doi.org/10.3324/..

12

Author Correction: Transcriptomic profiles and 5-year resul..:

Al-Sawaf, Othman ; Zhang, Can ; Jin, Hyun Yong...
Nature Communications. 14 (2023) 1 - p. , 2023

Link: https://doi.org/10.1038/..

13

S200: IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATI..:

Langerbeins, Petra ; Robrecht, Sandra ; Nieper, Pascal...
HemaSphere. 7 (2023) S3 - p. e9488123 , 2023

Link: https://doi.org/10.1097/..

14

Tislelizumab plus zanubrutinib for Richter transformation: ..:

Al-Sawaf, Othman ; Ligtvoet, Rudy ; Robrecht, Sandra...
Nature Medicine. 30 (2023) 1 - p. 240-248 , 2023

Link: https://doi.org/10.1038/..

15

P623: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PIRTO..:

Al-Sawaf, Othman ; Jen, Min-Hua ; Hess, Lisa...
HemaSphere. 7 (2023) S3 - p. e26114b3 , 2023

Link: https://doi.org/10.1097/..